DK1830887T3 - Antitrombotiske dobbelt-inhibitorer omfattende et biotin-reststof - Google Patents

Antitrombotiske dobbelt-inhibitorer omfattende et biotin-reststof

Info

Publication number
DK1830887T3
DK1830887T3 DK05821769.6T DK05821769T DK1830887T3 DK 1830887 T3 DK1830887 T3 DK 1830887T3 DK 05821769 T DK05821769 T DK 05821769T DK 1830887 T3 DK1830887 T3 DK 1830887T3
Authority
DK
Denmark
Prior art keywords
antithrombotic
biotin residue
double inhibitors
inhibitors
double
Prior art date
Application number
DK05821769.6T
Other languages
English (en)
Inventor
Kort Martin De
Boeckel Constant Van
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Application granted granted Critical
Publication of DK1830887T3 publication Critical patent/DK1830887T3/da

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cardiology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Oncology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK05821769.6T 2004-12-23 2005-12-21 Antitrombotiske dobbelt-inhibitorer omfattende et biotin-reststof DK1830887T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04106964 2004-12-23
PCT/EP2005/057011 WO2006067173A2 (en) 2004-12-23 2005-12-21 Antithrombotic dual inhibitors comprising a biotin residue

Publications (1)

Publication Number Publication Date
DK1830887T3 true DK1830887T3 (da) 2011-06-06

Family

ID=35160114

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05821769.6T DK1830887T3 (da) 2004-12-23 2005-12-21 Antitrombotiske dobbelt-inhibitorer omfattende et biotin-reststof

Country Status (29)

Country Link
US (3) US8168595B2 (da)
EP (1) EP1830887B1 (da)
JP (2) JP5130051B2 (da)
KR (1) KR101284922B1 (da)
CN (1) CN101087622A (da)
AR (1) AR053657A1 (da)
AT (1) ATE500846T1 (da)
AU (1) AU2005318134B2 (da)
BR (1) BRPI0518560A2 (da)
CA (1) CA2592436C (da)
DE (1) DE602005026859D1 (da)
DK (1) DK1830887T3 (da)
ES (1) ES2361921T3 (da)
HK (1) HK1106712A1 (da)
HR (1) HRP20110330T1 (da)
IL (2) IL183713A (da)
MX (1) MX2007007837A (da)
MY (1) MY146121A (da)
NO (1) NO20072878L (da)
NZ (1) NZ555739A (da)
PE (1) PE20060773A1 (da)
PL (1) PL1830887T3 (da)
PT (1) PT1830887E (da)
RU (1) RU2403259C2 (da)
SI (1) SI1830887T1 (da)
TW (1) TWI403334B (da)
UA (1) UA88793C2 (da)
WO (1) WO2006067173A2 (da)
ZA (1) ZA200705088B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI403334B (zh) * 2004-12-23 2013-08-01 Merck Sharp & Dohme 包含生物素殘基之抗血栓雙重抑制劑
JP6109574B2 (ja) 2009-12-18 2017-04-05 カタラン、フランス、バインハイム、ソシエテ、アノニムCatalent France Beinheim Sa 合成オリゴサッカリドを含有する医薬経口剤形
FR2974478A1 (fr) 2011-04-28 2012-11-02 Endotis Pharma Conjugues d'oligosaccharides en prevention des lesions d'ischemie-reperfusion
EP2721044B1 (en) 2011-06-17 2015-11-18 Carbomimetics Synthetic pentasaccharides having short half-life and high activity
WO2013007762A1 (en) 2011-07-11 2013-01-17 Endotis Pharma Combination of an anticoagulant and avidin useful in surgical intervention and clinical procedure
US10660973B2 (en) 2015-04-28 2020-05-26 Duke University Thrombus imaging aptamers and methods of using same
CN109982707A (zh) 2016-09-16 2019-07-05 杜克大学 血管性血友病因子(vwf)靶向剂及其使用方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252951A (en) * 1979-10-09 1981-02-24 Eli Lilly And Company Isolation of syn-7-(2-amino-4-thiazolyl)-(methoxyimino)acetamido-3-acetoxymethyl-3-cephem-4-carboxylic acid
DK0454220T3 (da) 1990-04-23 1993-11-22 Sanofi Elf Carbohydratderivater omfattende en trisaccharidenhed
IL102758A (en) 1991-08-23 1997-03-18 Akzo Nv Glycosaminoglycanoid derivatives, their preparation and pharmaceutical compositions comprising them
ATE190619T1 (de) 1993-09-01 2000-04-15 Akzo Nobel Nv Biskonjugate, die zwei saccharide und einen spacer enthalten
FR2749849B1 (fr) * 1996-06-14 1998-09-04 Sanofi Sa Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2751334B1 (fr) 1996-07-19 1998-10-16 Sanofi Sa Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2773804B1 (fr) 1998-01-19 2000-02-18 Sanofi Sa Polysaccharides de synthese, procede pour leur preparation et compositions pharmaceutiques le contenant
FR2773801B1 (fr) * 1998-01-19 2000-05-12 Sanofi Sa Nouveaux pentasaccharides, procedes pour leurs preparations et compositions pharmaceutiques les contenant
CN1261450C (zh) * 1998-06-17 2006-06-28 阿克佐诺贝尔公司 抗血栓形成化合物
TWI289566B (en) * 1999-12-07 2007-11-11 N.V.Organon Antithrombotic compound
FR2814463B1 (fr) 2000-09-22 2002-11-15 Sanofi Synthelabo Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine
TWI403334B (zh) * 2004-12-23 2013-08-01 Merck Sharp & Dohme 包含生物素殘基之抗血栓雙重抑制劑
CN101312747B (zh) * 2005-10-10 2013-03-20 Msd欧斯股份有限公司 包括生物素标记的抗血栓形成双重抑制剂

Also Published As

Publication number Publication date
WO2006067173A2 (en) 2006-06-29
PT1830887E (pt) 2011-05-31
ES2361921T3 (es) 2011-06-24
MY146121A (en) 2012-06-29
EP1830887B1 (en) 2011-03-09
ATE500846T1 (de) 2011-03-15
IL217047A0 (en) 2012-01-31
WO2006067173A3 (en) 2007-04-26
RU2007127859A (ru) 2009-01-27
BRPI0518560A2 (pt) 2008-11-25
MX2007007837A (es) 2007-07-25
TW200633724A (en) 2006-10-01
TWI403334B (zh) 2013-08-01
US8168595B2 (en) 2012-05-01
JP5632886B2 (ja) 2014-11-26
JP5130051B2 (ja) 2013-01-30
EP1830887A2 (en) 2007-09-12
CA2592436A1 (en) 2006-06-29
KR20070092304A (ko) 2007-09-12
NZ555739A (en) 2009-11-27
AU2005318134B2 (en) 2010-05-20
US20120238512A1 (en) 2012-09-20
US20120245109A1 (en) 2012-09-27
AR053657A1 (es) 2007-05-16
PE20060773A1 (es) 2006-09-01
IL183713A (en) 2013-07-31
DE602005026859D1 (de) 2011-04-21
KR101284922B1 (ko) 2013-07-10
CN101087622A (zh) 2007-12-12
RU2403259C2 (ru) 2010-11-10
IL183713A0 (en) 2007-09-20
US8445450B2 (en) 2013-05-21
CA2592436C (en) 2012-04-17
US20100004186A1 (en) 2010-01-07
JP2008525373A (ja) 2008-07-17
AU2005318134A1 (en) 2006-06-29
HK1106712A1 (en) 2008-03-20
PL1830887T3 (pl) 2011-07-29
SI1830887T1 (sl) 2011-06-30
HRP20110330T1 (hr) 2011-06-30
JP2013035851A (ja) 2013-02-21
UA88793C2 (ru) 2009-11-25
ZA200705088B (en) 2008-08-27
NO20072878L (no) 2007-09-17

Similar Documents

Publication Publication Date Title
NO2022026I1 (no) Secukinumab - forlenget SPC
IL179398A0 (en) Dpp-ib inhibitors
DK1805446T3 (da) Rørsamling
DE502005009190D1 (de) Verteilergetriebe
ATE335426T1 (de) Ausziehführungsgarnitur für schubladen
ATE545642T1 (de) Mmp-inhibitoren
DK1830887T3 (da) Antitrombotiske dobbelt-inhibitorer omfattende et biotin-reststof
HK1101881A1 (en) Antithrombotic compound
DE602004008208D1 (de) Ein verbinder
DE602005013012D1 (de) Ein Verbinder
DE602005005120D1 (de) Ein Steckverbinder
FI20041057A0 (fi) Pelkistysainekoostumus
DK1799707T3 (da) Rekombineret Kunitztypeinhibitor
ZA200802993B (en) Anticoagulant antithrombotic dual inhibitors comprising a biotin label
DE602005003405D1 (de) Ein Verbinder
ITMI20041935A1 (it) Struttura di solaio perfezionata
GB0421356D0 (en) Inhibitors
FR2879415B1 (fr) Epingle a chignon
DE602005025674D1 (de) Inhibitor für darmpolypen
FR2879934B1 (fr) Sterilisateur a outils
GB0405053D0 (en) JNK inhibitors
ITPD20050090A1 (it) Banco frigorifero a vasca
SE0201628D0 (sv) VoIP till en vanlig telefon
UA10709S (uk) Журнал
ITSV20040037A1 (it) Parete modulare